Recent advances in understanding the pathogenesis of rheumatic diseases have expanded the use of IL-6Ri to other rheumatic conditions, including AOSD, Giant Cell Arteritis, Behçet’s Disease, and Polymyalgia Rheumatica, thus positioning IL-6 or its receptor blockade as a novel strategy for managing certain rheumatic ailments. This evidence concerns the gene IL6 and adult-onset Still disease.